The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-0604
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2025
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Riabina M.V.

FGBU Moskovskiĭ nauchno-issledovatel'skiĭ institut glaznykh bolezneĭ im. Gel'mgol'tsa Minzdrava RF, Moskva

Chesnokova N.B.

FGBU Moskovskiĭ nauchno-issledovatel'skiĭ institut glaznykh bolezneĭ im. Gel'mgol'tsa Minzdrava RF, Moskva

Okhotsimskaia T.D.

FGBU Moskovskiĭ nauchno-issledovatel'skiĭ institut glaznykh bolezneĭ im. Gel'mgol'tsa Minzdrava RF, Moskva

Kuznetsova T.P.

FGBU Moskovskiĭ nauchno-issledovatel'skiĭ institut glaznykh bolezneĭ im. Gel'mgol'tsa Minzdrava RF, Moskva

The pathogenetic substantiation of the use of angiotensin-converting enzyme for the treatment of diabetic retinopathy

Authors:

Riabina M.V., Chesnokova N.B., Okhotsimskaia T.D., Kuznetsova T.P.

More about the authors

Journal: Problems of Endocrinology. 2012;58(5): 37‑40

Views: 772

Downloaded: 11

Download PDF (RU)
Contact the author
Table of contents

THE PATHOGENETIC SUBSTANTIATION OF THE USE OF ANGIOTENSIN-CONVERTING ENZYME FOR THE TREATMENT OF DIABETIC RETINOPATHY
THE PATHOGENETIC SUBSTANTIATION OF THE USE OF ANGIOTENSIN-CONVERTING ENZYME FOR THE TREATMENT OF DIABETIC RETINOPATHY

To cite this article:

Riabina MV, Chesnokova NB, Okhotsimskaia TD, Kuznetsova TP. The pathogenetic substantiation of the use of angiotensin-converting enzyme for the treatment of diabetic retinopathy. Problems of Endocrinology. 2012;58(5):37‑40. (In Russ.)

МСФ на ЯМ
Close metadata
Recommended articles:
Outcomes of bima­nual vitreoretinal surgery in the treatment of diabetic reti­nopathy complications. Russian Annals of Ophthalmology. 2024;(2-2):21-27
Prevalence of diabetic reti­nopathy asse­ssed using two-field mydriatic fundus photography. Russian Annals of Ophthalmology. 2024;(4):60-67
Obje­ctive stru­ctural and functional moni­toring of poly­peptide reti­nal neuroprotective therapy in diabetic reti­nopathy. Russian Annals of Ophthalmology. 2024;(5):97-104
Diabetic reti­nopathy and pregnancy. Russian Annals of Ophthalmology. 2024;(6):145-151
The influence of demo­graphic factors and major como­rbidities on serum circulating regu­latory microRNAs in patients with coro­nary artery athe­rosclerosis and thoracic aortic aneurysm: a single-center cohort study. Russian Journal of Cardiology and Cardiovascular Surgery. 2025;(2):174-182

The objective of the present work was to study visual functions, as well as changes in the systemic and local renin-angiotensin system before and after intake of the ACE inhibitor perindopril in 65 patients (130 eyes) presenting with diabetic retinopathy. The treatment caused the most pronounced changes in the patients with preproliferative diabetic retinopathy including the two-fold (p<0.05) decrease of ACE activity in the blood and its 7.5-fold (p<0.05) increase in the tears. These effects appear to be attributable to the action of perindopril on the levels of the proangiogenic factors known to be elevated in the patients with severe retinal ischemia. The treatment of patients with diabetic macular oedema with perindopril resulted in the decrease of the retinal thickness from 392.5±46.7 to 347.2±39.6 mcm in the absence of significant improvement in the acuteness of vision. All the patients experienced a significant reduction in the level of glycosylated hemoglobin.

Keywords:

diabetic retinopathy
renin-angiotensin system
ACE inhibitors

Authors:

Riabina M.V.

FGBU Moskovskiĭ nauchno-issledovatel'skiĭ institut glaznykh bolezneĭ im. Gel'mgol'tsa Minzdrava RF, Moskva

Chesnokova N.B.

FGBU Moskovskiĭ nauchno-issledovatel'skiĭ institut glaznykh bolezneĭ im. Gel'mgol'tsa Minzdrava RF, Moskva

Okhotsimskaia T.D.

FGBU Moskovskiĭ nauchno-issledovatel'skiĭ institut glaznykh bolezneĭ im. Gel'mgol'tsa Minzdrava RF, Moskva

Kuznetsova T.P.

FGBU Moskovskiĭ nauchno-issledovatel'skiĭ institut glaznykh bolezneĭ im. Gel'mgol'tsa Minzdrava RF, Moskva

List of references:

  1. Balabolkin M.I. Diabetologiya. M: Meditsina 2000; 345.
  2. Dedov I.I., Shestakova M.V. Sakharnyi diabet i arterial'naya gipertenziya. M: MIA 2006; 345.
  3. Antonetti D.A., Klein R., Gardner T.W. Diabetic retinopathy. N Engl J Med 2012; 366: 13: 1227-1239.
  4. Lang G.E. Diabetic retinopathy. Development in ophthalmology. Basel: Karger 2007; 39.
  5. Opie L.N. Angiotensin-Converting Enzyme Inhibitors. The Advance Continues. New York: Author,s Publishing House 1999; 315.
  6. Karpov Yu.A. Arterial'naya gipertoniya u bol'nykh sakharnym diabetom: osnovnye napravleniya lecheniya. Rus med zhurn 2001; 9: 24: 11-15.
  7. Hammes H.P., Porta M. Experimental Approaches to Diabetic Retinopathy. Frontiers of Diabets. Basel: Karger 2010; 20.
  8. Dancer A.H. Local renin-angiotesin system: the unanswered questions. Int J Biochem Cell Biol 2003; 35: 759-768.
  9. Fletcher E.L., Phipps J.A., Ward M.M., Vessey K.A., Wilkinson-Berka J.L. The renin-angiotensin system in retinal health and disease: Its influence on neurons, glia and the vasculature. Prog Retin Eye Res 2010; 29: 4: 284-311.
  10. Kohner E.M. The renin-angiotensin system and diabetic retinopathy. Klin Wochenschr 1992; 69: Suppl 29: 25-27.
  11. Hammes H.P., Feng Y., Pfister F., Brownlee M. Diabetic Retinopathy: Targeting Vasoregression. Diabetes 2011; 60: 1: 9-16.
  12. Pavlenko T.A. Angiotenzin-prevrashchayushchii ferment v tkanevykh strukturakh i zhidkikh sredakh glaza v norme i patologii, puti regulyatsii: Avtoref. dis. ... kand. med. nauk. M 2009.
  13. Wilkinson-Berka J.L. Angiotensin and diabetic retinopathy. Int J Biochem Cell Biol 2006; 38: 5-6: 752-765.
  14. Neroev V.V., Ryabina M.V., Okhotsimskaya T.D., Zueva M.V., Tsapenko I.V. O primenenii preparata "Perindopril" v lechenii bol'nykh diabeticheskoi retinopatiei. Vestn oftal'mol 2006; 4: 123: 4: 31-33.
  15. Neroev V.V., Chesnokova N.B., Okhotsimskaya T.D., Ryabina M.V., Kost O.A., Nikol'skaya I.I., Pavlenko T.A. Aktivnost' angio­tenzinprevrashchayushchego fermenta v krovi i sleze u bol'nykh s diabeticheskoi retinopatiei. Vestn oftal'mol 2006; 3: 122: 3: 11-14.
  16. Altynbaev U.R. Prognozirovanie i profilaktika oslozhnenii khirurgicheskogo lecheniya proliferativnoi diabeticheskoi retinopatii: Avtoref. dis. ... kand. med. nauk. Ufa 2006.
  17. Larsen M., Hommel E., Parving H.H., Lund-Andersen H. Protective effect of captopril on the blood-retina barrier in normotensive insulin-dependent diabetic patients with nephropathy and background retinopathy. Graefes Arch Clin Exp Ophthalmol 1990; 228: 505-509.
  18. Chase H.P., Garg S.K., Harris S., Hoops S., Jackson W.E., Holmes D.L. Angiotensin-converting enzyme inhibitor treatment for young normotensive diabetic subjects: a two-year trial. Ann Ophthalmol 1993; 25: 284-289.
  19. Chaturvedi N., Porta M., Klein R., Orchard T., Fuller J., Parving H.H., Bilous R., Sjolie A.K. for the DIRECT Programme Study Group: Effect of candesartan on prevention (DIRECT-Prevent 1) and progression (DIRECT-Protect 1) of retinopathy in type 1 diabetes: randomised, placebo-controlled trials. Lancet 2008; 372: 1394-1402.
  20. Chaturvedi N., Sjolie A.-K., Stephenson J.M., Abrahamian H., Keipes M., Castellarin A., Rogulja-Pepeonik Z., Fuller J.H. the EUCLID Study Group: Effect of lisinopril on progression of retinopathy in normotensive people with type 1 diabetes. Lancet 1998; 351: 28-31.

Close metadata

Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.